Twitter LinkedIn Français English ABOUT ERYTECH WHO WE ARE Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS®platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. The proof of concept of eryaspase as a cancer metabolism agent was established in different trials in acute lymphoblastic leukemia (ALL) and pancreatic cancer. An investigator sponsored Phase 2 trial (IST) evaluating the use of eryaspase in ALL patients who developed hypersensitivity reactions to pegylated asparaginase recently reported positive results, based on which the Company intends to request approval in the United States and potentially other territories. The Company is also pursuing a Phase 1 investigator-sponsored clinical trial in first-line pancreatic cancer. About Us Our Mission Our values Management Team Board of Directors Erytech PharmaSA 60 Avenue Rockefeller 69008 Lyon France Erytech Pharma Inc. 1 Main Street, Suite 300 Cambridge, MA 02142 USA About Us Technology Platform Pipeline Investors Newsroom Contact Opens in a new tab Opens in a new tab Terms & Conditions Copyright © 2021. Erytech Pharma. All rights reserved. Français English

Skip to main navigation Home Careers Contact French English Investor Relations Investors Press Releases Corporate Governance Stock Market Data SEC Filings AMF Regulated Information Shareholders Meeting Financial calendar Analyst Coverage Webcasts Corporate Presentation 2021 2020 2019 2018 2017 2016 2015 General meeting 2019 Documents 2019 General Meeting Preparatory Documents Convening Notice Auditor's special report Statutory auditors’ report on the consolidated financial statements Statutory auditors’ report on the financial statements Voting rights on May 17, 2019 AGM Board of directors’ report(English) AGM Board of directors’ report (French) Request form of documents related to the General Meeting Postal voting form and proxy form Voting results by resolution Print Page RSS Feeds E-mail Alerts IR Contact Erytech PharmaSA 60 Avenue Rockefeller 69008 Lyon France Erytech Pharma Inc. One Main Street Suite 1150 Cambridge, Massachusetts 02142, USA About Us Technology Platform Pipeline Investors Newsroom Contact Copyright © 2021. Erytech Pharma. All rights reserved. Terms & Conditions